article thumbnail

UCPMP 2024 Quiz

PharmaState Academy

UCPMP 2024 Quiz Take part in this quiz to explore and learn more about the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024. UCPMP 2024 Quiz The number of attempts remaining is 2 1 / 15 What is the appropriate way to use healthcare professional endorsements in drug promotions? How to Participate?

article thumbnail

New Year, New Goals: 2024

The Thyroid Pharmacist

I am hoping to feel more settled in 2024. I am wrapping up some projects in early 2024 and I am carving out more time for myself and my own healing. You can learn more about the results here and be the first to be notified the next time we run it in Fall 2024. Gut Recovery Program (est.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Could GSK myelofibrosis treatment gain EU-first approval?

European Pharmaceutical Review

In these clinical trials, the most common adverse reactions were diarrhoea, thrombocytopaenia, nausea, headache, dizziness, fatigue, asthenia, abdominal pain and cough. GSK shared that a decision on marketing authorisation for momelotinib in the EU is expected by early 2024.

article thumbnail

FDA approves first treatment for geographic atrophy

European Pharmaceutical Review

A marketing authorisation application (MAA) is under review by the European Medicines Agency (EMA) with a regulatory decision expected in early 2024. The safety profile of SYFOVRE is well-demonstrated following ~12,000 injections. SYFOVRE is expected to be available by the beginning of March 2023.

article thumbnail

Moderna receives U.S. FDA approval for RSV vaccine mRESVIA(R)

Express Pharma

The most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia. by the 2024/2025 respiratory virus season,” the statement informs. No serious safety concerns were identified in the Phase 3 trial. The post Moderna receives U.S.

article thumbnail

Novavax’s updated Covid-19 vaccine receives FDA emergency use authorisation

Pharmaceutical Business Review

The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) [NVX-CoV2705] is now authorised for active immunisation against Covid-19. The CDC’s Advisory Committee on Immunization Practices unanimously recommended the use of the 2024-2025 COVID-19 vaccines for individuals as young as six months in June this year.

article thumbnail

OPDP Says TV Ad is Out of Bounds with Fourth Untitled Letter of 2024

FDA Law Blog: Biosimilars

By Sarah Wicks & Dara Katcher Levy — FDA’s Office of Prescription Drug Promotion (OPDP) has issued its fourth Untitled Letter of 2024 – this one to AbbVie, Inc. The approved labeling for UBRELVY includes a warning and precaution regarding hypersensitivity reactions, with the most common adverse reactions being nausea and somnolence.